GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.
Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond.
The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 899.0K |
| Three Month Average Volume | -100,000 |
| High Low | |
| Fifty-Two Week High | 23.36 USD |
| Fifty-Two Week Low | 12.51 USD |
| Fifty-Two Week High Date | 20 Jun 2024 |
| Fifty-Two Week Low Date | 12 Jun 2024 |
| Price and Volume | |
| Current Price | 14.11 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -19.49% |
| Thirteen Week Relative Price Change | -99,999.99% |
| Twenty-Six Week Relative Price Change | -99,999.99% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -99,999.99% |
| Price Change | |
| One Day Price Change | -4.79% |
| Thirteen Week Price Change | -99,999.99% |
| Twenty-Six Week Price Change | -99,999.99% |
| Five Day Price Change | -8.44% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -99,999.99% |
| Month-to-Date Price Change | -8.26% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 137.3328 USD |
| Book Value Per Share (Most Recent Quarter) | 86.80196 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.63759 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 19.61635 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -23.38355 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 3.50678 USD |
| Revenue Per Share (Trailing Twelve Months) | 3.9123 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -55.20471 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -99.94366 USD |
| Normalized (Last Fiscal Year) | -37.19111 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -55.20471 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -99.94366 USD |
| Including Extraordinary Items (Last Fiscal Year) | -55.20471 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -99.94366 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.66429 USD |
| Cash Per Share (Most Recent Quarter) | 30.88152 USD |
| Cash Flow Per Share (Last Fiscal Year) | -49.22742 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -97.11731 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -24.11404 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,348 |
| Cash Flow Revenue (Trailing Twelve Months) | -616 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2,702.82% |
| Pretax Margin (Last Fiscal Year) | -1,619.29% |
| Pretax Margin (5 Year) | -5,181.28% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 41.11% |
| Gross Margin (Trailing Twelve Months) | 44.06% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,627.61% |
| Operating Margin (Trailing Twelve Months) | -2,711.61% |
| Operating Margin (5 Year) | -5,193.50% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,574.23% |
| Net Profit Margin (Trailing Twelve Months) | -2,627.35% |
| Net Profit Margin (5 Year) | -5,118.86% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 43.44% |
| Tangible Book Value (5 Year) | -34.93% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 42.63% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -4.22% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -602.23% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -958,845,000 |
| Net Debt (Last Fiscal Year) | -97,287,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 4 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -608,687,000 |
| Free Cash Flow (Trailing Twelve Months) | -676,392,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -33.12% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -47.45% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -35.35% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -58.91% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -34.27% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -48.55% |